Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Dahl, ML' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 74 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Kvist, EE; Al-Shurbaji, A; Dahl, ML; Nordin, C; Alvan, G; Stahle, L
      Quantitative pharmacogenetics of nortriptyline - A novel approach

      CLINICAL PHARMACOKINETICS
    2. Scordo, MG; Aklillu, E; Yasar, U; Dahl, ML; Spina, E; Ingelman-Sundberg, M
      Genetic polymorphism of cytochrome P4502C9 in a Caucasian and a black African population

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    3. Roh, HK; Chung, JY; Oh, DY; Park, CS; Svensson, JO; Dahl, ML; Bertilsson, L
      Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    4. Carlsson, B; Olsson, G; Reis, M; Walinder, J; Nordin, C; Lundmark, J; Scordo, MG; Dahl, ML; Bengtsson, F; Ahlner, J
      Enantioselective analysis of citalopram and metabolites in adolescents

      THERAPEUTIC DRUG MONITORING
    5. Yasar, U; Tybring, G; Hidestrand, M; Oscarson, M; Ingelman-Sundberg, M; Dahl, ML; Eliasson, E
      Role of CYP2C9 polymorphism in losartan oxidation

      DRUG METABOLISM AND DISPOSITION
    6. Alvan, G; Bertilsson, L; Dahl, ML; Ingelman-Sundberg, M; Sjoqvist, F
      Moving toward genetic profiling in patient care: The scope and rationale of pharmacogenetic/ecogenetic investigation

      DRUG METABOLISM AND DISPOSITION
    7. Kirchheiner, J; Brosen, K; Dahl, ML; Gram, LF; Kasper, S; Roots, I; Sjoqvist, F; Spina, E; Brockmoller, J
      CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages

      ACTA PSYCHIATRICA SCANDINAVICA
    8. Benitez, J; Dahl, ML; Spina, E; Carrillo, JA
      Genetic and environmental factors causing variability in psychotropic drugresponse

      INTERINDIVIDUAL VARIABILITY IN HUMAN DRUG METABOLISM
    9. Llerena, A; Kiivet, RA; Dahl, ML; Vega, JS; Rootslane, L; Wettermark, B
      Psychotropic drug use in non-psychiatric departments of three European university hospitals

      NORDIC JOURNAL OF PSYCHIATRY
    10. Dalen, P; Dahl, ML; Andersson, K; Bertilsson, L
      Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    11. Carrillo, JA; Christensen, M; Ramos, SI; Alm, C; Dahl, ML; Benitez, J; Bertilsson, L
      Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine

      THERAPEUTIC DRUG MONITORING
    12. Dahl, ML; Sjoqvist, F
      Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics

      THERAPEUTIC DRUG MONITORING
    13. Scordo, MG; Spina, E; Romeo, P; Dahl, ML; Bertilsson, L; Johansson, I; Sjoqvist, F
      CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    14. Sagar, M; Tybring, G; Dahl, ML; Bertilsson, L; Seensalu, R
      Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism

      GASTROENTEROLOGY
    15. Dalen, P; Dahl, ML; Eichelbaum, M; Bertilsson, L; Wilkinson, GR
      Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes

      PHARMACOGENETICS
    16. Wennerholm, A; Johansson, I; Massele, AY; Jande, M; Alm, C; Aden-Abdi, Y; Dahl, ML; Ingelman-Sundberg, M; Bertilsson, L; Gustafsson, LL
      Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype

      PHARMACOGENETICS
    17. Bernal, ML; Sinues, B; Johansson, I; McLellan, RA; Wennerholm, A; Dahl, ML; Ingelman-Sundberg, M; Bertilsson, L
      Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine

      PHARMACOGENETICS
    18. Yasar, U; Eliasson, E; Dahl, ML; Johansson, I; Ingelman-Sundberg, M; Sjoqvist, F
      Validation of methods for CYP2C9 genotyping: Frequencies of mutant allelesin a Swedish population (vol 254, pg 628, 1999)

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    19. Yasar, U; Eliasson, E; Dahl, ML; Johansson, I; Ingelman-Sundberg, M; Sjoqvist, F
      Validation of methods for CYP2C9 genotyping: Frequencies of mutant allelesin a Swedish population

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    20. Scordo, MG; Spina, E; Facciola, G; Avenoso, A; Johansson, I; Dahl, ML
      Cytochrome P450 2D6 genotype and steady state plasma levels of risperidoneand 9-hydroxyrisperidone

      PSYCHOPHARMACOLOGY
    21. Yamada, H; Dahl, ML; Viitanen, M; Winblad, B; Sjoqvist, F; Lannfelt, L
      No association between familial Alzheimer disease and cytochrome P450 polymorphisms

      ALZHEIMER DISEASE & ASSOCIATED DISORDERS
    22. EIERMANN B; EDLUND PO; TJERNBERG A; DALEN P; DAHL ML; BERTILSSON L
      1-HYDROXYLATION AND 3-HYDROXYLATION, IN ADDITION TO 4-HYDROXYLATION, OF DEBRISOQUINE ARE CATALYZED BY CYTOCHROME-P450 2D6 IN HUMANS

      Drug metabolism and disposition
    23. KIIVET RA; DAHL ML; LLERENA A; MAIMETS M; WETTERMARK B; BERECZ R
      ANTIBIOTIC USE IN 3 EUROPEAN UNIVERSITY HOSPITALS

      Scandinavian journal of infectious diseases
    24. SAGAR M; SEENSALU R; TYBRING G; DAHL ML; BERTILSSON L
      CYP2C19 GENOTYPE AND PHENOTYPE DETERMINED WITH OMEPRAZOLE IN PATIENTSWITH ACID-RELATED DISORDERS WITH AND WITHOUT HELICOBACTER-PYLORI INFECTION

      Scandinavian journal of gastroenterology
    25. YAMADA H; DAHL ML; LANNFELT L; VIITANEN M; WINBLAD B; SJOQVIST F
      CYP2D6 AND CYP2C19 GENOTYPES IN AN ELDERLY SWEDISH POPULATION

      European Journal of Clinical Pharmacology
    26. SAGAR M; TYBRING G; DAHL ML; BERTILSSON L; SEENSALU R
      THE EFFECT OF OMEPRAZOLE ON INTRAGASTRIC PH AND GASTRIN-LEVELS IS DETERMINED BY THE CYP2C19 POLYMORPHISM MORE THAN BY HELICOBACTER-PYLORI INFECTION IN PATIENTS WITH ACID-RELATED DISEASE

      Gastroenterology
    27. OSCARSON M; GULLSTEN H; RAUTIO A; BERNAL ML; SINUES B; DAHL ML; STENGARD JH; PELKONEN O; RAUNIO H; INGELMANSUNDBERG M
      GENOTYPING OF HUMAN CYTOCHROME-P450 2A6 (CYP2A6), A NICOTINE C-OXIDASE

      FEBS letters
    28. YUE QY; ZHONG ZH; TYBRING G; DALEN P; DAHL ML; BERTILSSON L; SJOQVIST F
      PHARMACOKINETICS OF NORTRIPTYLINE AND ITS 10-HYDROXY METABOLITE IN CHINESE SUBJECTS OF DIFFERENT CYP2D6 GENOTYPES

      Clinical pharmacology and therapeutics
    29. HERRLIN K; MASSELE AY; JANDE M; ALM C; TYBRING G; ABDI YA; WENNERHOLM A; JOHANSSON I; DAHL ML; BERTILSSON L; GUSTAFSSON LL
      BANTU TANZANIANS HAVE A DECREASED CAPACITY TO METABOLIZE OMEPRAZOLE AND MEPHENYTOIN IN RELATION TO THEIR CYP2C19 GENOTYPE

      Clinical pharmacology and therapeutics
    30. SCHEININ H; ANTTILA M; DAHL ML; KARNANI H; NYMAN L; TAAVITSAINEN P; PELKONEN O; BERTILSSON L
      CYP2D6 POLYMORPHISM IS NOT CRUCIAL FOR THE DISPOSITION OF SELEGILINE

      Clinical pharmacology and therapeutics
    31. DALEN P; DAHL ML; RUIZ MLB; NORDIN J; BERTILSSON L
      10-HYDROXYLATION OF NORTRIPTYLINE IN WHITE PERSONS WITH 0-FUNCTIONAL,1-FUNCTIONAL, 2-FUNCTIONAL, 3-FUNCTIONAL, AND 13-FUNCTIONAL C-UPSILON-P2D6 GENES

      Clinical pharmacology and therapeutics
    32. DAHL ML; VOORTMAN G; ALM C; ELWIN CE; DELBRESSINE L; VOS R; BOGAARDS JJP; BERTILSSON L
      IN-VITRO AND IN-VIVO STUDIES ON THE DISPOSITION OF MIRTAZAPINE IN HUMANS

      Clinical drug investigation
    33. SYVALAHTI EKG; TAIMINEN T; SAARIJARVI S; LEHTO H; NIEMI H; AHOLA V; DAHL ML; SALOKANGAS RKR
      CITALOPRAM CAUSES NO SIGNIFICANT ALTERATIONS IN PLASMA NEUROLEPTIC LEVELS IN SCHIZOPHRENIC-PATIENTS

      Journal of international medical research
    34. MIHARA K; OTANI K; TYBRING G; DAHL ML; BERTILSSON L; KANEKO S
      THE CYP2D6 GENOTYPE AND PLASMA-CONCENTRATIONS OF MIANSERIN ENANTIOMERS IN RELATION TO THERAPEUTIC RESPONSE TO MIANSERIN IN DEPRESSED JAPANESE PATIENTS

      Journal of clinical psychopharmacology
    35. DALEN P; FRENGELL C; DAHL ML; SJOQVIST F
      QUICK ONSET OF SEVERE ABDOMINAL-PAIN AFTER CODEINE IN AN ULTRARAPID METABOLIZER OF DEBRISOQUINE

      Therapeutic drug monitoring
    36. NORDIN C; DAHL ML; ERIKSSON M; SJOBERG S
      IS THE CHOLESTEROL-LOWERING EFFECT OF SIMVASTATIN INFLUENCED BY CYP2D6 POLYMORPHISM

      Lancet
    37. MARANDI T; DAHL ML; RAGO L; KIIVET R; SJOQVIST F
      DEBRISOQUINE AND S-MEPHENYTOIN HYDROXYLATION POLYMORPHISMS IN A RUSSIAN POPULATION LIVING IN ESTONIA

      European Journal of Clinical Pharmacology
    38. HU Y; OSCARSON M; JOHANSSON I; YUE QY; DAHL ML; TABONE M; ARINCO S; ALBANO E; INGELMANSUNDBERG M
      GENETIC-POLYMORPHISM OF HUMAN CYP2E1 - CHARACTERIZATION OF 2 VARIANT ALLELES

      Molecular pharmacology
    39. SAGAR M; BERTILSSON L; DAHL ML; TYBRING G; SEENSALU R
      INDIVIDUAL METABOLISM OF OMEPRAZOLE IS DETERMINED BY THE GENOTYPE OF THE ENZYME CYP2C19 WITHOUT RELATION TO HELICOBACTER-PYLORI INFECTION

      Gastroenterology
    40. DAHL ML; OLHAGER E; AHLNER J
      PAROXETINE WITHDRAWAL SYNDROME IN A NEONATE

      British Journal of Psychiatry
    41. JOHANSSON K; BRYDING G; DAHL ML; HOLMGREN P; VIITANEN M
      TRAFFIC DANGEROUS DRUGS ARE OFTEN FOUND IN FATALLY INJURED OLDER MALEDRIVERS

      Journal of the American Geriatrics Society
    42. SPIGSET O; HEDENMALM K; DAHL ML; WIHOLM BE; DAHLQVIST R
      SEIZURES AND MYOCLONUS ASSOCIATED WITH ANTIDEPRESSANT TREATMENT - ASSESSMENT OF POTENTIAL RISK-FACTORS, INCLUDING CYP2D6 AND CYP2C19 POLYMORPHISMS, AND TREATMENT WITH CYP2D6 INHIBITORS

      Acta psychiatrica Scandinavica
    43. BERTILSSON L; DAHL ML; TYBRING G
      PHARMACOGENETICS OF ANTIDEPRESSANTS - CLINICAL ASPECTS

      Acta psychiatrica Scandinavica
    44. BERTILSSON L; DAHL ML
      POLYMORPHIC DRUG OXIDATION - RELEVANCE TO THE TREATMENT OF PSYCHIATRIC-DISORDERS

      CNS DRUGS
    45. ROH HK; DAHL ML; TYBRING G; YAMADA H; CHA YN; BERTILSSON L
      CYP2C19 GENOTYPE AND PHENOTYPE DETERMINED BY OMEPRAZOLE IN A KOREAN POPULATION

      Pharmacogenetics
    46. ROH HK; DAHL ML; JOHANSSON I; INGELMANSUNDBERG M; CHA YN; BERTILSSON L
      DEBRISOQUINE AND S-MEPHENYTOIN HYDROXYLATION PHENOTYPES AND GENOTYPESIN A KOREAN POPULATION

      Pharmacogenetics
    47. JOHANSSON I; LUNDQVIST E; DAHL ML; INGELMANSUNDBERG M
      PCR-BASED GENOTYPING FOR DUPLICATED AND DELETED CYP2D6 GENES

      Pharmacogenetics
    48. GUSTAFSSON LL; ERIKSSON LS; DAHL ML; ELEBORG L; ERICZON BG; NYBERG A
      CYCLOPHOSPHAMIDE-INDUCED ACUTE LIVER-FAILURE REQUIRING TRANSPLANTATION IN A PATIENT WITH GENETICALLY DEFICIENT DEBRISOQUINE METABOLISM - A CAUSAL RELATIONSHIP

      Journal of internal medicine
    49. NYBERG S; FARDE L; DENCKER SJ; MALM U; DAHL ML; HALLDIN C
      D2-RECEPTOR AND 5-HT2-RECEPTOR OCCUPANCY IN MEGA-DOSE TREATED SCHIZOPHRENIC-PATIENTS

      Schizophrenia research
    50. MARANDI T; DAHL ML; KIIVET RA; RAGO L; SJOQVIST F
      DEBRISOQUIN AND S-MEPHENYTOIN HYDROXYLATION PHENOTYPES AND CYP2D6 GENOTYPES IN AN ESTONIAN POPULATION

      Pharmacology & toxicology
    51. MASIMIREMBWA CM; GUSTAFSSON LL; DAHL ML; ABDI YA; HASLER JA
      LACK OF EFFECT OF CHLOROQUINE ON THE DEBRISOQUINE (CYP2D6) AND S-MEPHENYTOIN (CYP2C19) HYDROXYLATION PHENOTYPES

      British journal of clinical pharmacology
    52. CARRILLO JA; DAHL ML; SVENSSON JO; ALM C; RODRIGUEZ I; BERTILSSON L
      DISPOSITION OF FLUVOXAMINE IN HUMANS IS DETERMINED BY THE POLYMORPHICCYP2D6 AND ALSO BY THE CYP1A2 ACTIVITY

      Clinical pharmacology and therapeutics
    53. JERLING M; DAHL ML; ABERGWISTEDT A; LILJENBERG B; LANDELL NE; BERTILSSON L; SJOQVIST F
      THE CYP2D6 GENOTYPE PREDICTS THE ORAL CLEARANCE OF THE NEUROLEPTIC AGENTS PERPHENAZINE AND ZUCLOPENTHIXOL

      Clinical pharmacology and therapeutics
    54. DAHL ML; BERTILSSON L; NORDIN C
      STEADY-STATE PLASMA-LEVELS OF NORTRIPTYLINE AND ITS 1.0-HYDROXY METABOLITE - RELATIONSHIP TO THE CYP2D6 GENOTYPE

      Psychopharmacology
    55. CHANG M; DAHL ML; TYBRING G; GOTHARSON E; BERTILSSON L
      USE OF OMEPRAZOLE AS A PROBE DRUG FOR CYP2C19 PHENOTYPE IN SWEDISH CAUCASIANS - COMPARISON WITH S-MEPHENYTOIN HYDROXYLATION PHENOTYPE AND CYP2C19 GENOTYPE

      Pharmacogenetics
    56. DAHL ML; YUE QY; ROH HK; JOHANSSON I; SAWE J; SJOQVIST F; BERTILSSON L
      GENETIC-ANALYSIS OF THE CYP2D LOCUS IN RELATION TO DEBRISOQUINE HYDROXYLATION CAPACITY IN KOREAN, JAPANESE AND CHINESE SUBJECTS

      Pharmacogenetics
    57. KIIVET RA; LLERENA A; DAHL ML; ROOTSLANE L; VEGA JS; EKLUNDH T; SJOQVIST F
      PATTERNS OF DRUG-TREATMENT OF SCHIZOPHRENIC-PATIENTS IN ESTONIA, SPAIN AND SWEDEN

      British journal of clinical pharmacology
    58. CHANG M; TYBRING G; DAHL ML; GOTHARSON E; SAGAR M; SEENSALU R; BERTILSSON L
      INTERPHENOTYPE DIFFERENCES IN DISPOSITION AND EFFECT ON GASTRIN-LEVELS OF OMEPRAZOLE - SUITABILITY OF OMEPRAZOLE AS A PROBE FOR CYP2C19

      British journal of clinical pharmacology
    59. ARTHUR H; DAHL ML; SIWERS B; SJOQVIST F
      POLYMORPHIC DRUG-METABOLISM IN SCHIZOPHRENIC-PATIENTS WITH TARDIVE-DYSKINESIA

      Journal of clinical psychopharmacology
    60. DAHL ML; JOHANSSON I; BERTILSSON L; INGELMANSUNDBERG M; SJOQVIST F
      ULTRARAPID HYDROXYLATION OF DEBRISOQUINE IN A SWEDISH POPULATION - ANALYSIS OF THE MOLECULAR-GENETIC BASIS

      The Journal of pharmacology and experimental therapeutics
    61. NYBERG S; FARDE L; HALLDIN C; DAHL ML; BERTILSSON L
      D-2 DOPAMINE-RECEPTOR OCCUPANCY DURING LOW-DOSE TREATMENT WITH HALOPERIDOL DECANOATE

      The American journal of psychiatry
    62. NYBERG S; DAHL ML; HALLDIN C
      A PET STUDY OF D-2, AND 5-HT2, RECEPTOR OCCUPANCY INDUCED BY RISPERIDONE IN POOR METABOLIZERS OF DEBRISOQUIN AND RISPERIDONE

      Psychopharmacology
    63. BERTILSSON L; CARRILLO JA; DAHL ML; LLERENA A; ALM C; BONDESSON U; LINDSTROM L; DELARUBIA IR; RAMOS S; BENITEZ J
      CLOZAPINE DISPOSITION COVARIES WITH CYP1A2 ACTIVITY DETERMINED BY A CAFFEINE TEST

      British journal of clinical pharmacology
    64. DAHL ML; LLERENA A; BONDESSON U; LINDSTROM L; BERTILSSON L
      DISPOSITION OF CLOZAPINE IN MAN - LACK OF ASSOCIATION WITH DEBRISOQUINE AND S-MEPHENYTOIN HYDROXYLATION POLYMORPHISMS

      British journal of clinical pharmacology
    65. ISHIZAKI T; SOHN DR; KOBAYASHI K; CHIBA K; LEE KH; SHIN SG; ANDERSSON T; REGARDH CG; LOU YC; ZHANG Y; DAHL ML; BERTILSSON L
      INTERETHNIC DIFFERENCES IN OMEPRAZOLE METABOLISM IN THE 2 S-MEPHENYTOIN HYDROXYLATION PHENOTYPES STUDIED IN CAUCASIANS AND ORIENTALS

      Therapeutic drug monitoring
    66. DAHL ML; LLERENA A; HERRAIZ AG; JOHANSSON I
      CONCORDANCE OF PHENOTYPE AND GENOTYPE FOR CYP2D6 - REPLY

      Clinical pharmacology and therapeutics
    67. DAHL ML; TYBRING G; ELWIN CE; ALM C; ANDREASSON K; GYLLENPALM M; BERTILSSON L
      STEREOSELECTIVE DISPOSITION OF MIANSERIN IS RELATED TO DEBRISOQUIN HYDROXYLATION POLYMORPHISM

      Clinical pharmacology and therapeutics
    68. DAHL ML; BERTILSSON L
      GENETICALLY VARIABLE METABOLISM OF ANTIDEPRESSANTS AND NEUROLEPTIC DRUGS IN MAN

      Pharmacogenetics
    69. BERTILSSON L; MEESE CO; YUE QY; DAHL ML; INGELMANSUNDBERG M; JOHANSSON I; SAWE J; EICHELBAUM M
      QUINIDINE INHIBITION OF DEBRISOQUINE S(-4-HYDROXYLATIONS AND 7-HYDROXYLATIONS IN CHINESE OF DIFFERENT CYP2D6 GENOTYPES())

      Pharmacogenetics
    70. DAHL ML; ISELIUS L; ALM C; SVENSSON JO; LEE D; JOHANSSON I; INGELMANSUNDBERG M; SJOQVIST F
      POLYMORPHIC 2-HYDROXYLATION OF DESIPRAMINE - A POPULATION AND FAMILY STUDY

      European Journal of Clinical Pharmacology
    71. JOHANSSON I; LUNDQVIST E; BERTILSSON L; DAHL ML; SJOQVIST F; INGELMANSUNDBERG M
      INHERITED AMPLIFICATION OF AN ACTIVE GENE IN THE CYTOCHROME-P450 CYP2D LOCUS AS A CAUSE OF ULTRARAPID METABOLISM OF DEBRISOQUINE

      Proceedings of the National Academy of Sciences of the United Statesof America
    72. CHUPP JP; JONES CR; DAHL ML
      NOVEL SYNTHESIS MODES AND PROPERTIES OF [1,4]BENZODIOXINOPYRIDAZINES[1]

      Journal of heterocyclic chemistry
    73. LLERENA A; HERRAIZ AG; COBALEDA J; JOHANSSON I; DAHL ML
      DEBRISOQUIN AND MEPHENYTOIN HYDROXYLATION PHENOTYPES AND CYP2D6 GENOTYPE IN PATIENTS TREATED WITH NEUROLEPTIC AND ANTIDEPRESSANT AGENTS

      Clinical pharmacology and therapeutics
    74. LLERENA A; ALM C; DAHL ML; EKQVIST B; BERTILSSON L
      HALOPERIDOL DISPOSITION IS DEPENDENT ON DEBRISOQUINE HYDROXYLATION PHENOTYPE

      Therapeutic drug monitoring


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/12/19 alle ore 14:47:16